NCT03698552 - ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome PositiveRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

ADCT-602

Starting dose of ADCT-602: 30 μg/kg given by vein.

Trial Locations (2)

77030

RECRUITING

M D Anderson Cancer Center, Houston

91016

RECRUITING

City of Hope Comprehensive Cancer, Monrovia